BAYTRIL Comprimé

Riik: Kanada

keel: prantsuse

Allikas: Health Canada

Toimeaine:

Enrofloxacine

Saadav alates:

ELANCO CANADA LIMITED

Annus:

68MG

Ravimvorm:

Comprimé

Koostis:

Enrofloxacine 68MG

Manustamisviis:

Orale

Ühikuid pakis:

50/250

Retsepti tüüp:

Prescription

Terapeutiline rühm:

Chats; Chiens

Toote kokkuvõte:

Numéro de groupe d'ingrédients actifs (GIA) :0121066004

Volitamisolek:

APPROUVÉ

Loa andmise kuupäev:

2021-01-06

Infovoldik

Pr
Baytril 22.7 mg and 68 mg Package Insert
04Jan2021
PR
BAYTRIL
1
22.7 MG AND 68 MG PACKAGE INSERT
2
DIN 02169444 - 22.7 mg
3
DIN 02169452 - 68 mg
4
_ _
5
_PR _BAYTRIL_ _
6
(ENROFLOXACIN)
7
ANTIMICROBIAL TABLETS
8
9
FOR VETERINARY USE ONLY
10
11
DESCRIPTION: Enrofloxacin is a synthetic chemo-therapeutic agent from
the class of
12
the quinolone carboxylic acid derivatives. It has antibacterial
activity against a broad
13
spectrum of Gram negative and Gram positive bacteria. (See Table 1).
It is rapidly
14
absorbed from the digestive tract, penetrating into all measured body
tissues and fluids.
15
(See Table 2). Tablets are available in three sizes (22.7, 68.0 mg
enrofloxacin).
16
17
CHEMICAL NOMENCLATURE:
1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-
18
dihydro-4-oxo-3-quinolinecarboxylic acid.
19
20
ACTIONS:
21
MICROBIOLOGY: Enrofloxacin, a 4-fluoroquinolone compound, is
bactericidal with activity
22
against a broad spectrum of both Gram negative and Gram positive
bacteria.
23
Fluoroquinolones elicit their bactericidal properties through
interactions with two
24
intercellular enzymes - DNA gyrase (DNA topoisomerase II) and DNA
topoisomerase
25
IV - which are essential for bacterial DNA transcription, synthesis
and replication. It is
26
believed that fluoroquinolones actively bind with DNA:ENZYME complexes
and thereby
27
inhibit the essential processes catalyzed by the enzymes (DNA
supercoiling and
28
chromosomal decatenation)
1
. The ultimate outcome of fluoroquinolone intervention is
29
DNA fragmentation and bacterial cell death.
2,3
30
31
Enrofloxacin minimum inhibitory concentrations (MICs) were determined
for canine and
32
feline bacterial isolates originating from natural infections of the
dermal, gastrointestinal,
33
respiratory and urinary systems. Seven hundred and thirty eight (738)
isolates were
34
collected from 14 different diagnostic laboratories located throughout
the United States.
35
Bacterial identity was confirmed by colony morphology, Gram stain and
biochemical
36
testing; for mycoplas